{
    "nctId": "NCT05288686",
    "briefTitle": "Use of Superparamagnetic Iron Oxide (SPIO) in Sentinel Lymph Node Detection for Breast Cancer",
    "officialTitle": "Use of Superparamagnetic Iron Oxide (SPIO) Versus Conventional Radioisotope and Patent Blue Dye in Sentinel Lymph Node Detection for Breast Cancer: a Randomized Controlled Trial",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer, Sentinel Lymph Node",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 282,
    "primaryOutcomeMeasure": "sentinel lymph node detection rate per patient",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* All patients with clinical T1-3N0 invasive ductal carcinoma or invasive lobular carcinoma planned for breast conservative surgery or mastectomy, with sentinel lymph node biopsy\n* Patients planned for upfront operation or neoadjuvant chemotherapy are allowed\n\nExclusion Criteria:\n\n* Patients with hypersensitivity to dextran compounds, iron or blue dye\n* Patients with iron overload disease\n* Pregnant or lactating patients\n* Patients with pacemaker or other implantable metallic devices in chest wall or prosthesis in shoulder\n* Mentally incompetent patients",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}